Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
GLP-1 coverage, Novo's strategy and Moderna's mRNA cancer vaccine data all moved health names.
TL;DR
- CNBC reported the Eli Lilly CEO saying 700,000 new seniors started GLP-1s after Medicare coverage, with 70% on Lilly drugs.
- MarketWatch reported Novo Nordisk's stock tumbling as doubts persisted about the Ozempic maker's strategy.
- MarketWatch also reported Moderna would reveal data for its mRNA cancer vaccine next month.
CNBC reported that Eli Lilly's CEO said 700,000 new seniors have started GLP-1s after Medicare coverage, and that 70% are on Lilly drugs. [1]
MarketWatch reported that Novo Nordisk's stock tumbled as doubts persisted about the Ozempic maker's strategy. [2]
MarketWatch also reported that Moderna will reveal data for its mRNA cancer vaccine next month. [3]
Why it matters
GLP-1 coverage is becoming a mass-market reimbursement story, so the read-through runs from drugmakers to insurers and to the wider health-spending debate.
Editor's note
Company claims are as reported by the outlets and were not independently verified; no medical or investment advice is offered.